Strategic partnership will develop a digital transformation roadmap and create opportunities for co-innovation in healthcare technologies
Pfizer calls upon global health leaders and organizations to join the Accord, bringing their expertise and resources to close the health equity gap
‘Infinite Care’ comprises two key pillars - Sparsh Sankalpa and Sparsh Sukshema
Multiples is the first private equity (PE) investor in the company
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
It is developing the drug candidate to potentially treat immunological diseases
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
The company exports mobile surgery equipment to over 100 countries from Pune
The company also raised Rs 270 crore investment from Temasek in 2019
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Subscribe To Our Newsletter & Stay Updated
